Protalix BioTherapeutics (PLX) Competitors $3.00 -0.01 (-0.17%) As of 12:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PLX vs. SYRE, MLYS, NTLA, NRIX, GYRE, RCUS, COLL, AVDL, VIR, and AVXLShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Avadel Pharmaceuticals (AVDL), Vir Biotechnology (VIR), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Spyre Therapeutics Mineralys Therapeutics Intellia Therapeutics Nurix Therapeutics Gyre Therapeutics Arcus Biosciences Collegium Pharmaceutical Avadel Pharmaceuticals Vir Biotechnology Anavex Life Sciences Protalix BioTherapeutics (NYSE:PLX) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability. Is PLX or SYRE more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Spyre Therapeutics N/A -210.01%-44.40% Which has more risk & volatility, PLX or SYRE? Protalix BioTherapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Does the media prefer PLX or SYRE? In the previous week, Spyre Therapeutics had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 5 mentions for Spyre Therapeutics and 3 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.43 beat Spyre Therapeutics' score of 1.16 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, PLX or SYRE? Protalix BioTherapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$53.40M4.38$8.31M$0.03100.00Spyre Therapeutics$890K992.86-$338.79M-$4.23-3.47 Does the MarketBeat Community favor PLX or SYRE? Spyre Therapeutics received 9 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Spyre Therapeutics an outperform vote while only 80.00% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1280.00% Underperform Votes320.00% Spyre TherapeuticsOutperform Votes21100.00% Underperform VotesNo Votes Do analysts rate PLX or SYRE? Protalix BioTherapeutics presently has a consensus target price of $15.00, indicating a potential upside of 400.00%. Spyre Therapeutics has a consensus target price of $49.57, indicating a potential upside of 238.14%. Given Protalix BioTherapeutics' higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Do institutionals & insiders have more ownership in PLX or SYRE? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 6.3% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummarySpyre Therapeutics beats Protalix BioTherapeutics on 11 of the 19 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$234.10M$2.95B$5.53B$18.96BDividend YieldN/A1.89%5.11%4.01%P/E Ratio-23.0830.0722.5132.87Price / Sales4.38494.82397.6228.03Price / Cash17.80168.6838.1817.52Price / Book6.383.176.734.47Net Income$8.31M-$72.35M$3.22B$1.02B7 Day Performance5.26%2.14%1.38%0.59%1 Month Performance15.83%5.67%2.79%-3.54%1 Year Performance158.62%-23.57%15.41%3.80% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.7898 of 5 stars$3.00-0.2%$15.00+400.8%+147.9%$234.49M$53.40M-23.12200Analyst RevisionNews CoveragePositive NewsSYRESpyre Therapeutics1.9349 of 5 stars$14.67+3.8%$49.57+237.9%-56.7%$884.25M$890,000.00-1.96100Upcoming EarningsNews CoveragePositive NewsMLYSMineralys Therapeutics2.3839 of 5 stars$13.56+1.6%$33.00+143.4%+16.9%$879.72MN/A-3.7328Upcoming EarningsShort Interest ↑News CoverageNTLAIntellia Therapeutics4.6615 of 5 stars$8.48+2.0%$36.68+332.6%-61.6%$877.82M$57.88M-1.56600Upcoming EarningsPositive NewsGap UpNRIXNurix Therapeutics1.9601 of 5 stars$11.47-0.8%$30.44+165.4%-14.7%$874.43M$56.42M-3.97300Analyst ForecastNews CoverageGYREGyre Therapeutics0.0669 of 5 stars$9.32+2.8%N/A-32.6%$873.69M$105.76M186.4040Upcoming EarningsNews CoverageRCUSArcus Biosciences2.3015 of 5 stars$8.25-0.6%$28.38+243.9%-44.4%$867.39M$258M-2.62500Upcoming EarningsNews CoveragePositive NewsGap DownCOLLCollegium Pharmaceutical4.0558 of 5 stars$26.87+0.3%$43.60+62.3%-28.4%$863.39M$631.45M11.58210Upcoming EarningsPositive NewsAVDLAvadel Pharmaceuticals2.5551 of 5 stars$8.75-0.2%$19.88+127.1%-53.0%$845.50M$169.12M-11.0870Upcoming EarningsPositive NewsVIRVir Biotechnology2.4833 of 5 stars$6.10-0.3%$33.57+450.4%-30.4%$842.19M$63.71M-1.56580AVXLAnavex Life Sciences3.8237 of 5 stars$9.58+1.7%$44.00+359.3%+152.3%$814.91MN/A-17.4240Upcoming EarningsNews Coverage Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Intellia Therapeutics Alternatives Nurix Therapeutics Alternatives Gyre Therapeutics Alternatives Arcus Biosciences Alternatives Collegium Pharmaceutical Alternatives Avadel Pharmaceuticals Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLX Stock Free PLX Stock Alerts